Floor Stam
CEO
reMYND
reMYND NV is a biotech company developing first-in-class treatments for Alzheimer's and Huntington's diseases by restoring synaptic function and cortico-striatal transmission through a proprietary drug discovery platform. Additionally, its Contract Research Organization provides in-vivo testing services using unique transgenic mouse models to evaluate the efficacy of experimental neurodegenerative therapies for global pharmaceutical clients.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$14.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Johan Cardoen
Chairman of reMYND’s Board
Product
Problem
Alzheimer's and Huntington's diseases lack effective treatments that restore lost synaptic function and cortico-striatal transmission, leading to progressive cognitive and motor decline. Current experimental therapies often fail to demonstrate efficacy in clinical trials due to the absence of predictive in-vivo models.
Solution
reMYND NV develops first-in-class treatments for neurodegenerative diseases, including Alzheimer's and Huntington's, by focusing on restoring cellular function. Their proprietary drug discovery platform identifies novel mechanisms-of-action and targets to develop small molecule therapeutics. In addition, reMYND operates a contract research organization (CRO) providing in-vivo testing services using unique transgenic mouse models to evaluate the efficacy of experimental neurodegenerative therapies. These models provide pivotal proof-of-concept data for candidate drugs in clinical development.
Target Audience
The primary customers are pharmaceutical companies developing treatments for Alzheimer's, Huntington's, and other neurodegenerative diseases, as well as researchers seeking advanced in-vivo models for preclinical drug evaluation.
Features
- Proprietary drug discovery platform for identifying novel targets and mechanisms-of-action in neurodegenerative diseases.
- ReS19-T: An investigational compound for the treatment of Alzheimer’s, currently in CTA-enabling studies.
- Transgenic mouse models for assessing the pharmacokinetics, pharmacodynamics, and efficacy of experimental treatments.
- In-vivo proof-of-concept data generation for candidate drugs.
- Models to demonstrate synergistic effects of drug combinations (e.g., BACE inhibitor and aBeta antibody).